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Osteoarthritis (OA) is a common chronic joint disorder with a multifactorial etiology including genetic
and environmental factors. Metabolic triggered inﬂammation, induced by nutrient overload and meta-
bolic surplus, consists of components such as obesity, pro-inﬂammatory cytokines and adipokines,
abnormal metabolites, acute phase proteins, vitamin D deﬁciency, and deregulated microRNAs that may
play a role in OA pathophysiology. Obesity-related metabolic factors, especially adipokines, contribute to
OA development by inducing pro-inﬂammatory cytokines and degradative enzymes, leading to cartilage
matrix impairment and subchondral bone remodeling. Ectopic metabolite deposition and low-grade
systemic inﬂammation can contribute to a toxic internal environment that exacerbates OA. Comple-
ment components highly expressed in osteoarthritic joints have also been proposed as causative factors.
Vitamin D deﬁciency has been associated with obesity and is implicated to be associated with cartilage
loss in OA. Metabolic microRNAs may explain the inﬂammatory link between obesity and OA. Therapies
targeting metabolic-triggered inﬂammation and its components are anticipated to have potential for the
treatment of OA.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a common disease characterized by joint
pain, impaired mobility, and synovial joint structural changes1. It is
no longer conceived as a simplex disease, but rather has a complex
etiology and new discoveries have differentiated OA into several
phenotypes, i.e., post-traumatic, ageing-related, genetic and
symptomatic2. A newly deﬁned phenotype of OA, namely ‘meta-
bolic OA’, has been associated withmetabolic syndrome (MetS) and
obesity3. Metabolic triggered inﬂammation (also called meta-
inﬂammation4), which can be a result of abnormalities in body
composition, adipokines, cytokines, complements, lipids and
vitamin D, has been implicated in the pathogenesis of OA (Fig. 1).
The incidence of obesity worldwide has increased dramatically
during recent decades. Accordingly, obesity and associated disorders
such as OA now constitute a serious threat to the current and future
health of both developed and developing populations. Strategies
targeting obesity-relatedmechanisms, e.g., meta-inﬂammation, may
be effective in preventing and slowing disease progression of OA.
The purpose of this narrative review is to examine the link betweeno: C. Ding, Private Bag 23,
; Fax: 61-3-62267704.
ng).
ternational. Published by Elsevier Lmeta-inﬂammation and OA, discussing how the components of
meta-inﬂammation contribute to OA, and to propose several po-
tential therapies modifying meta-inﬂammation in OA.
Metabolic triggered inﬂammation
Meta-inﬂammation is mainly caused by nutrient overload and
metabolic surplus5. Metabolic overload results in oxidative stress
and inﬂammation, which then triggers vicious stress cycles that
lead to cell dysfunction6. The components that make up the cluster
of MetS, such as overweight, dyslipidemia and impaired glucose
tolerance, have been involved in meta-inﬂammation. Other com-
ponents as summarized in Table I also have roles to play.
Recent studies have found that centrally placed adipose tissues
(e.g., visceral fat) is a crucial site in the generation of inﬂammatory
responses and mediators7. Abdominal (central) obesity is associ-
ated with increased incidence of metabolic diseases, which are
closely related to chronic inﬂammation through elevated levels of
cytokines, acute-phase inﬂammatory components (complements
and C reactive protein, CRP) and other mediators6,8. Furthermore,
adipocytes as the key cells that regulate the interactions between
endothelial cells (EC) and macrophages also synthesize numerous
cytokines such as interleukin (IL)-6, IL-1, and tumor necrosis factor-
a (TNF-a) and adipokines such as leptin, adiponectin, resistin, and
visfatin9.td. All rights reserved.
Fig. 1. Pathogenic role of metabolic triggered inﬂammation in OA. Abnormal dietary factors (such as lipids and glucose) and dysfunctional fat produce an excess of adipokines
(leptin, resistin, visfatin etc.) that are able to increase risk of OA by inducing pro-inﬂammatory mediators (cytokines, CRP, complements). The levels of lean mass, muscle strength
and anti-inﬂammatory mediators, including IL-10, IL-4 and adiponectin, are decreased in OA. Other common metabolites such as vitamin D not only interact with other inﬂam-
matory mediators, but also involve in cartilage and bone development and metabolism. Abnormal expressions of microRNAs are associated with meta-inﬂammation and joint
structural alterations.
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could disturb the integration of systemic metabolism, simulta-
neously leading to inﬂammatory responses. In addition, a group of
acute phase protein such as complement components, stimulated
by pro-inﬂammatory cytokines, could lead to a chronic inﬂamma-
tory state and metabolic dysfunction10. Individuals with obesity
and/ormetabolic diseases have lowcirculating 25-hydroxy-vitamin
D (25-(OH)D)11, which can be induced by factors including leptin
and IL-612. At the molecular level, microRNAs are differentially
expressed in fat depots and can regulatemeta-inﬂammation, which
potentially contribute to the pathogenesis of obesity-associated
complications13.Direct evidence of meta-inﬂammation in OA
Body fat may be better than body mass index (BMI) in predicting OA
Obesity (deﬁned by BMI > 30 kg/m2) is a signiﬁcant risk factor
for the onset and progression of OA2. BMI was negatively associated
with knee cartilage volume and cartilage thickness, and positively
associated with tibial bone area and knee cartilage defects14,15.
However, BMI is only a surrogate measure of obesity that cannot
discriminate fat and lean mass, which may have different effects on
OA. Indeed, central adiposity, measured by waist-to-hip ratio and
waist circumference, were better predictors of OA incidence than
BMI16. Also fat mass and skeletal muscle mass had a better statis-
tical ﬁt than BMI to explain both the odds of having and the severity
of knee OA17. Furthermore, body fat adversely affects knee cartilage
loss over time, whereas lean mass is protective, and body fat was
better than BMI in predicting tibial cartilage loss18. Additionally,
waist circumference and fat mass were associated with increased
knee cartilage defects19, reduced knee cartilage volume and
increased bone marrow lesions (BMLs)20. Total body fat, trunk fat,waist-hip ratio and waist circumference were all associated with
increased knee pain over 5 years21. In addition, some local fat tis-
sues, such as infrapatellar fat pad (IPFP), may act as modulators in
OA. IPFP was considered as a source of local inﬂammatory media-
tors and thus an active osteoarthritic tissue22, but it also has a
beneﬁcial effect possibly through biomechanical mechanisms, as
supported by a recent study suggesting that IPFP size was nega-
tively associated with OA disease severity independent of BMI and
total body fat23. Taken together, all these suggest that it is central
adiposity, rather than extra body weight, that may play a major role
in the structural and symptomatic changes of OA.
Adipokines
Adipose tissue is considered as a metabolic endocrine organ
during systematic metabolic process. As obesity develops, adipo-
cytes release active components such as leptin, adiponectin, resis-
tin and visfatin, which lead to metabolic dysfunction in OA
patients24. Adipokines can disrupt cartilage homeostasis through
directly inducing joint structural degradation or regulating local
inﬂammatory processes25.
Leptin
Leptin, a small (16 kd) polypeptide encoded by the obese (ob)
gene, is produced predominantly in white adipose tissue and reg-
ulates energy intake and expenditure at the hypothalamic level26.
Leptin was positively correlated with BMI, fat mass and body
weight among people with OA27. The strong synergistic relation-
ship between leptin and pro-inﬂammatory cytokines has been
discovered in OA, as leptin enhanced the expression of inducible
nitric oxide synthase (iNOS), cyclooxygenase (COX-2), prosta-
glandin E2 (PGE2), IL-6 and IL-8 in cartilage28. The elevated
expressions of leptin and its receptor isoform (Ob-Rb) had
Table I
Key components of metabolic triggered inﬂammation and their roles in OA
Key components Roles in OA
Body composition18e20 Body fat is associated with more knee cartilage
loss; lean mass has an opposite effect; body
composition measures were better than BMI in
predicting OA
Adipokines14,24,25,38 Leptin, resistin and visfatin have emerged as pro-
inﬂammatory and pro-catabolic factors in OA;
circulating leptin is associated with increased
knee cartilage loss and joint pain; adiponectin
may have an anti-inﬂammatory effect and thus be
beneﬁcial on OA
Cytokines49,52,56 Cytokines can be produced by adipose tissue;
circulating or local cytokines (IL-6, TNF-a, IL-17,
IL-18) were associated with ROA, cartilage loss
and/or knee pain. Intervention such as exercise
can increase anti-inﬂammatory cytokine IL-10 in
OA.
Acute-phase
inﬂammatory
components62e64
CRP is associated with decreased knee cartilage
volume and increased knee pain. Complements
such as C1s, C4A, factor B, C3, C5, MAC and
transcripts that encoding complements effectors
are all abnormally expressed in OA. COMP-C3b
complexes can be found in OA.
Nutrients66,68,74 Lipids accumulate in cartilage with increasing
histological lesion severity; serum cholesterol and
triglyceride levels were associated increased risk
of osteoarthritic changes, but HDL was associated
with decreased risk; statin use in high doses may
reduce OA risk.
Hyperglycaemia has detrimental effects on
cartilage; diabetes could be an independent risk
factor for OA, leading to the concept of a diabetes-
induced OA phenotype.
Vitamin D deﬁciency76,77 Vitamin D deﬁciency can be a result of metabolic
triggered inﬂammation; low serum levels of 25-
(OH)D were associated with increased
progression of knee ROA and increased cartilage
loss.
Reactive
nitrogen and
oxygen species104,105
Nitric oxide (NO) and reactive oxygen species are
increased in OA, and associated with increased
inﬂammatory cytokines. IL-1-induced OA
cartilage damage is inhibited by a NO synthase 2
inhibitor or by superoxide dismutase, but a recent
RCT failed to show positive effects of iNOS
inhibition on symptoms and disease progression
of knee OA.
MicroRNAs81e83 MiRNAs is involved inmeta-inﬂammation and the
regulation of cartilage development and
homeostasis; nine miRNAs up-regulated (i.e.,
miR-22 and miR-103) and seven down-regulated
(i.e., miR29a, miR-140 and miR-25) in
osteoarthritic cartilage; the various functions of
miRNAs include suppression of inﬂammatory
cytokines, ADAMTS, COX-2, iNOS and MMPs
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trix metalloproteinases (MMPs) and IL-1b production29. Grifﬁn
et al. asserted that leptin, rather than obesity per se, was essential
for joint cartilage degradation, because impaired leptin signaling
was unable to trigger systemic inﬂammation and knee OA in leptin-
deﬁcient (ob/ob) and leptin receptoredeﬁcient (db/db) mice,
although adiposity was increased by approximately 10-fold30.
In clinical studies, serum leptin was associated with reduced
cartilage volume14, increased hip joint space narrowing (JSN)31 and
increased loss of cartilage thickness32, independent of BMI. More
interestingly, the signiﬁcant associations between obesity mea-
sures and all the above structural outcomes were largely mediated
by leptin14,31,32, suggesting that metabolic rather than mechanical
mechanisms underlie the association between obesity and cartilage
loss. Similarly, studies reported that plasma or synovial leptin levels
were associated with increased joint pain in OA33, and theassociation between obesity and joint pain was substantially
reduced after adjustment for synovial leptin33. All these suggest
that leptin has a catabolic effect, but it may also exert anabolic
activity in chondrocytes by inducing the production of growth
factors including insulin-like growth factor-1 (IGF-1) and trans-
forming growth factor-b (TGF-b)34. Leptin may have opposite ef-
fects on radiographic knee OA in men and women, as a study
reported that leptin levels were signiﬁcantly associated with
increased radiographic knee OA among obese and non-obese
women, but associated with decreased radiographic knee OA
among obese and non-obese men35.
Adiponectin
Adiponectin is a 244-amino acid protein expressed in adipose
tissue that exerts its biological activity through two cell receptors,
AdipoR1 and AdipoR236. In cultured chondrocytes, adiponectin is
involved in cartilage hemostasis by increasing tissue inhibitor of
metalloprotease (TIMP)-2 and decreasing IL-1b-induced MMP-337.
In addition, adiponectin up-regulates IL-10 in human macrophages
to increase TIMP-1 levels and to prevent the extracellular matrix
(ECM) degradation8. An epidemiological study reported that pa-
tients in the two higher tertiles of adiponectin had a decreased risk
of 70% for hand OA progression in comparison with patients in the
lowest tertile over 6 years38. The adiponectin/leptin ratio in syno-
vial ﬂuid was associated with reduced knee pain in patients with
severe knee OA39. Collectively, these ﬁndings indicate that adipo-
nectin may have a beneﬁcial effect on OA. On the other hand, some
studies reported that adiponectin induced nitric oxide synthase
type II and pro-inﬂammatory cytokines in chondrocytes40, and its
plasma level was associated with increased OA radiographic
severity41. These discrepancies may be due to the existence of
different isoforms of adiponectin, which may have different effects
on OA42.
Other adipokines
Resistin augments the expression of cytokines and chemokines,
up-regulates MMP-1 and -13, but down-regulates type II collagen
a1 (COL2A1) and aggrecan expressions in human chondrocytes43.
Another catabolic adipokine, visfatin, could induce the expression
of MMPs and reduce the synthesis of matrix components (for
example, low-molecular-weight proteoglycans) in OA chon-
drocytes44. Chemerin is recently described as a chemokine/adipo-
kine that regulates metabolic function and is associated with the
severity of knee OA45. All these suggest that adipokines are
important metabolic mediators involved in the inﬂammatory pro-
cess of OA.
Cytokines
Pro-inﬂammatory cytokines
In OA adipose tissue, there are numerous pro-inﬂammatory
cytokines produced by adipocytes and inﬁltrating macrophages
which are modulated by adipokines46. These cytokines induce the
release of matrix anabolic enzymes and inhibit the synthesis of
ECM components such as proteoglycan and type II collagen47;
subsequently, accelerate cartilage degradation or induce bone
reabsorption in OA48. IL-1b, TNF-a and IL-6 appear to be the major
cytokines involved in the pathogenesis of OA. Other pro-
inﬂammatory cytokines including IL-15, IL-17, IL-18, leukemia
inhibitory factor (LIF) and chemokines such as CC-chemokine
ligand (CCL5) and IL-8 are also increased in OA and are signiﬁ-
cantly associated with increased MMPs or down-regulated pro-
teoglycan levels49. A single injection of IL-17A into the rat knee joint
elicited a slowly developing and long-lasting sensitization of
nociceptive C ﬁbers of the joint to mechanical stimuli, which was
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the potential to act as a pain mediator in knee OA50.
Clinical and epidemiological studies have conﬁrmed the roles of
cytokines in OA. Livshits et al. reported that serum IL-6 level was a
signiﬁcant predictor in women of radiographic OA (ROA) 5e10
years later51. Our group reported that higher baseline IL-6 and TNF-
a levels were associated with more severe ROA and predicted
greater loss of cartilage over 3 years52; baseline IL-6 and TNF-a
levels also predicted an increase in knee pain over 5 years in older
adults53. Synovial ﬂuid/serum levels of IL-17 were associated with
greater ROA and knee pain54. Furthermore, IL-18 and IL-1b in
subjects with knee OA were strongly correlated with JSN and
osteophytes55. Synovial ﬂuid IL-18 was also positively associated
with knee pain and OA severity as measured by bone scintigraphy.
Besides this, it also predicted an increase in osteophyte score over 3
years55.
Anti-inﬂammatory cytokines
Apart from pro-inﬂammatory cytokines, adipose tissue also se-
crets regulatory cytokines. Anti-inﬂammatory cytokines such as
IL-4, IL-10 and IL-13 were elevated in OA tissues, inhibiting the
expression of IL-1b, TNF-a and proteases, and increasing IL-1 re-
ceptor antagonist and TIMP production49. The protective role of
IL-10 in cartilage and synovial membrane has been shown to be
through counteracting the detrimental effects of pro-inﬂammatory
cytokines, and exercise caused an increase in both intra-articular
and peri-synovial concentrations of IL-10 in females with knee
OA56.
Acute-phase inﬂammatory components: hs-CRP and complements
The key acute phase protein CRP is regulated by pro-
inﬂammatory cytokines and mostly produced by hepatocytes and
adipocytes. CRP levels were elevated in obese subjects57 and had
been added into other conventional risk factors for the prediction of
age-related diseases58.
Studies have demonstrated that levels of hs-CRP are associated
with decreased cartilage volume and OA progression59. In older
adults, both baseline and change in hs-CRP were positively asso-
ciated with change in knee pain particularly inﬂammatory phe-
notypes (sitting/lying or nocturnal) over 5 years53. Furthermore,
the plasma level of hs-CRP in hip or knee OA patients with in-
ﬂammatory inﬁltrates in synovial membrane was signiﬁcantly
higher than those without inﬂammation60. Plasma hs-CRP was
signiﬁcantly associated with synovial ﬂuid IL-6, degree of synovial
inﬂammatory inﬁltration and BMI, suggesting that systemic hs-CRP
levels may reﬂect synovial inﬂammation in OA patients, presum-
ably by means of synovial IL-6 production60.
Recently we performed ameta-analysis to systematically review
the literature for the relationship between circulating hs-CRP and
OA phenotypes61. We found that hs-CRP levels in OAweremodestly
higher than controls, and associated with increased pain and
decreased physical function. All these associations appeared to be
independent of BMI. In contrast, there was no signiﬁcant associa-
tion between hs-CRP and ROA, suggesting low-grade systemic
inﬂammation may play a greater role in symptoms rather than
radiographic changes of OA.
Pathological complement activation can occur in the affected
joints propagating a disease process leading to tissue destruction in
rheumatoid arthritis and OA62. To identify the role of complements
in the inﬂammatory cascades of OA, Wang et al. reported that
components of the classical pathway (C1s and C4A), the alternative
pathway (factor B) and the central components C3 and C5 were all
abnormally expressed in synovial ﬂuid of human osteoarthritic
joints63. They also discovered that membrane attack complex(MAC), which comprised the complement effector C5b-9, were
aberrantly expressed in synovial ﬂuids from individuals with OA.
Furthermore, MAC can also induce chondrocyte expression of pro-
inﬂammatory cytokines, COX 2 and cartilage-degrading enzymes63.
In addition, the expression of properdin, a positive regulator of the
alternative complement pathway, and CD59, an inhibitor of MAC
formation, were signiﬁcantly up-regulated in early OA synovium
compared with advanced stage64.
In an OA model induced by medial meniscectomy, C5-deﬁcient
mice had less cartilage loss, osteophyte formation and synovitis
than C5-sufﬁcient wide-type mice. Targeting C5 using a neutral-
izing monoclonal antibody or a fusion protein attenuated the
development of OA in wild-type mice63. Mice deﬁcient in C6, an
integral component of the MAC, also developed less OA and syno-
vitis, whereas mice deﬁcient in CD59a developedmore63. Emerging
evidence has shown that osteoarthritic cartilage or components of
cartilage ECM (i.e., ﬁbromodulin, cartilage oligomeric matrix pro-
tein (COMP)) can activate complements such as C5b-9, C1q and
C3b63, and subsequently trigger the complement cascade which
promotes joint pathology of OA. COMP-C3b complexes can be
found in patients with joint diseases63.
Nutrients
Altered nutrition metabolism such as abnormal lipids, choles-
terol and glucose may be one of the underlying causes of OA. In OA
cartilage, accumulation of lipid, total fatty acids and arachidonic
acid were elevated with increasing histological lesion severity65.
Lipid peroxidation in chondrocytes or synoviocytes was linked to
cartilage matrix protein oxidation and degradation, supporting the
role of lipid metabolism in the pathogenesis of cartilage aging66.
Interestingly, the genetic expressions of cholesterol efﬂux, which
can decrease lipid deposits in the chondrocytes, were signiﬁcantly
lower in osteoarthritic cartilage, suggesting that impaired expres-
sion of cholesterol regulatory genes may be a critical player in OA67.
Proteomic analyses in isolated chondrocytes and osteoarthritic
cartilage have also shown that some proteins, such as peroxisome
proliferators-activated receptors (PPAR) and apolipoproteins, were
relevant to lipid metabolism68.
Some epidemiological studies have shown serum cholesterol to
be a risk factor for OA development68, and two recent studies re-
ported that while serum cholesterol and triglyceride levels were
associated with the incidence of knee subchondral BMLs over
2 years69, high-density lipoprotein (HDL) cholesterol was protec-
tive against BML change70.
Long-chain omega-3 polyunsaturated fatty acids (PUFAs) could
decrease inﬂammatory eicosanoids, cytokines and reactive oxygen
species65. A recent animal study showed that small amounts of
omega-3 PUFAs in a high-fat diet were sufﬁcient to mitigate injury-
induced OA, decrease leptin and resistin levels and enhance wound
repair, while saturated fatty acids (SFAs) or omega-6 PUFAs inde-
pendently increased OA severity, synovitis and osteophyte forma-
tion71. In the Multi-center OA Study, subjects with higher levels of
total omega-3 PUFAs had lower patellofemoral cartilage loss, but
subjects with higher levels of omega-6 PUFAs tended to have higher
synovitis72.
Hyperglycaemia can trigger a low-grade systemic inﬂammation
that may have an impact on the progression of OA. Indeed, several
epidemiological studies reported that diabetes could be an inde-
pendent risk factor for OA, leading to the concept of a diabetes-
induced OA phenotype73. Hyperglycaemia has detrimental effects
on cartilage and these effects are mediated by oxidative stress and
advanced glycation end-products (AGEs), which induce chon-
drocyte dysfunction, matrix stiffness and subchondral bone
destruction74. Increased fasting serum glucose concentration in a
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knee cartilage and higher incidence of BMLs52,75, supporting the
potential role of hyperglycaemia in OA.
Complementary evidence of meta-inﬂammation in OA
Vitamin D deﬁciency
Change in 25-(OH)D levels per annumwas negatively predicted
by baseline body fat, leptin, IL-6 and total cholesterol/high-density
lipoprotein (HDL) ratio12, suggesting vitamin D deﬁciency is
involved in the meta-inﬂammation. Vitamin D deﬁciency (25-(OH)
D < 50 nmol/L) was found to be positively associated with the
development and worsening of knee OA, including cartilage loss,
increased JSN76,77 and pain78. In a systematic review, we reported
that there was moderate evidence showing that low levels of 25-
(OH)D were associated with increased progression of knee ROA.
Strong evidence for an association between 25-(OH)D and knee
cartilage loss was apparent when JSN and changes in cartilage
volume were considered collectively as knee cartilage loss.
MicroRNAs in OA
MicroRNAs (miRNAs) are a class of non-coding endogenous RNA
molecules, only 18e25 nucleotides in length, which have been
shown to possess signiﬁcant modulatory effects in biological and
pathological processes including adipocyte differentiation,
apoptosis, metabolic regulation and inﬂammation79, and are thus
involved in the process of meta-inﬂammation. Indeed, a study re-
ported there were a series of signiﬁcant correlations between
miRNAs expression in omental adipose tissue and serum inﬂam-
matory/metabolic biomarkers80.
Iliopoulos et al. investigated expressions of 365 miRNAs in
articular cartilage of OA patients undergoing knee replacement
surgery. They identiﬁed 16 miRNAs differentially expressed in
osteoarthritic in contrast to normal cartilage with nine up-
regulated (i.e., miR-22 and miR-103) and seven down-regulated
(i.e., miR29a, miR-140 and miR-25). Furthermore, the expres-
sions of miR-22 and miR-103 in cartilage were positively corre-
lated with BMI in OA patients, but miR-25, miR-337 and miR-29a
were the opposite81. By matching miRNA and protein data, Ilio-
poulos et al. reported that miRNA-gene target pairs were involved
in cartilage homeostasis (i.e., miR-140-ADAMTS-5) and in meta-
bolic pathways (i.e., miR-29a-leptin)81. Moreover, inhibition of
miR-22 in osteoarthritic chondrocytes could block the inﬂamma-
tory process and up-regulate the expression of cartilage repair
protein aggrecan81. Miyaki et al. reported that expression of miR-
140 was signiﬁcantly reduced in OA than normal cartilage82.
Yamasaki et al. showed that miR-146a was expressed intensely in
cartilage with a low osteoarthritic grade and its expression was
decreased in parallel with the levels of MMP-1383. Recently, Vonk
et al. reported that overexpression of hsa-miR-148a in osteoar-
thritic chondrocytes increased the production of type II collagen
and proteoglycans, and inhibited MMP-13 and ADAMTS-5 gene
expression84. These ﬁndings have conﬁrmed that miRNAs most
likely modulate cartilage metabolism through metabolic and in-
ﬂammatory mechanisms in OA.
Modiﬁcation of meta-inﬂammation in OA
Weight loss and exercise
As weight loss and exercise have been strongly recommended
for the management of knee OA symptoms, the underlying mech-
anisms may partly be due to modiﬁcation of meta-inﬂammation.Among overweight and/or obese adults with knee OA, intensive
weight loss induced by diet and exercise resulted in signiﬁcant
improvements in knee pain, function, quality of life, muscle
strength and endurance, as well as reductions in body fat, trunk fat,
plasma IL-6 levels, leptin, leptin: adiponectin ratio and/or
lipids85,86. Intensive weight loss induced by a gastric surgery87 or
diet88 in obese knee OA patients also resulted in signiﬁcant relief of
knee pain as well as decreases in IL-6, hs-CRP and/or COMP. While
muscle strength training alone showed signiﬁcant improvements
in leptin levels as well as knee pain, disability, muscle strength and
functional performance89, acute resistance exercise caused an in-
crease in intraarticular and peri-synovial IL-10 and a decrease in
intraarticular COMP in women with knee OA56.
Anti-cytokine/adipokine therapies
IL-1 and TNF-a are the pivotal cytokines involved in OA phys-
iopathology; hence, strategies targeting these inﬂammatory cyto-
kines seem to be rational therapies for OA. However, the results
from clinical trials are not promising so far. A randomized
controlled trial (RCT) showed that one single intra-articular injec-
tion of anakinra (a recombinant IL-1Ra) was not associated with
improvements in OA symptoms compared with placebo in 12
weeks of follow-up90. Another RCT reported that subcutaneously
administration of a monoclonal antibody (AMG 108) against the
functional type 1 receptor of IL-1 did not signiﬁcantly relieve knee
pain compared with placebo after 12 weeks treatment despite the
numerical differences favoring efﬁcacy of AMG 10891. Diacerein, an
anthraquinone that interferes with IL-1, has been conﬁrmed by a
recent systematic review to have minimal beneﬁts on knee symp-
toms and JSN in OA92.
Similarly, TNF-a antagonists, such as adalimumab and inﬂix-
imab, have shown inconsistent clinical efﬁcacies in OA. A recent
RCT reported that adalimumab was not superior to placebo to
alleviate pain in patients with hand OA not responding to analge-
sics and NSAIDs93, but it signiﬁcantly halted the progression of joint
damage compared to placebo in hand OA patients with palpable
soft tissue swelling94. An open-label trial reported that adalimu-
mab treatment for 12 weeks signiﬁcantly improved knee pain,
stiffness, function, joint swelling in knee OA patients with evidence
of effusion95.
These inconsistent results may be due to variations in factors
such as small sample size, heterogeneous samples (inﬂammatory
phenotype would be more responsive to anti-inﬂammatory ther-
apy), and a short treatment period. Adipokines (e.g., leptin) and
other cytokines (e.g., IL-6 and IL-17) are closely related to OA, but
there are no clinical trials reporting efﬁcacies of anti-IL-6, 17 or
leptin therapies on OA so far. Further well-designed RCTs using
sensitive measures such as MRI are required to test if anti-cytokine/
adipokine therapies will relieve symptoms and slow disease pro-
gression of OA.
Metabolite modulators
Lipid-lowering drugs, e.g., statins, may have the potential for OA
treatment. Use of statins was associated with more than a 50%
reduction in overall progression of knee OA over 6.5 years96.
Although it is reported that statin use was not associated with
improvements in knee pain, function or structural progression over
a 4-year study period97, a 10-year observational study indicated
that only a higher therapeutic dose of statin (>18 mg daily), with a
treatment-duration of at least 2 years, was associated with a sig-
niﬁcant reduction in clinical OA compared to non-statin use98.
Currently a RCT is being performed to examine if atorvastatin has a
disease-modifying effect in symptomatic knee OA in Australia
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Vitamin D supplementation
Vitamin D supplementation signiﬁcantly reduced serum levels
of IL-6 and decreased leptin: adiponectin ratio in obese objects99,
and thus may affect OA through modifying meta-inﬂammation. A
RCT showed that vitamin D supplementation for 2 years at a dose
sufﬁcient to elevate 25-(OH)D plasma levels to higher than 36 ng/
ml did not reduce knee pain or cartilage volume loss in patients
with symptomatic OA. However, in those with low baseline 25-
(OH)D (<15 ng/ml), vitamin D supplementation had larger effects
on knee pain and change in cartilage volume than in those who
received placebo, although these were not signiﬁcant due to the
small sample size100. In another RCT, knee OA patients with vitamin
D deﬁciency were included and it was found that vitamin D sup-
plementation signiﬁcantly improved knee pain and function
compared to placebo, but had no effect on progression of ROA,
possibly due to a short follow-up period101. It is most likely that
vitamin D supplementation is only effective in thosewith vitamin D
deﬁciency patients. Further well-designed RCTs are required to
determine whether vitamin D supplementation can reduce symp-
toms and disease progression of OA102.
Modiﬁcation of miRNAs
In recent years, anti-miRNAs ormiRNA-mimics have emerged as
useful tools for inhibiting/over-expressing the function of miRNAs,
and thus may be used for the treatment of miRNAs-related diseases
such as OA. Some pre-clinical studies have provided promising
evidence. Transfection with ds-miR-140 in chondrocytes down-
regulated IL-1b-induced a disintegrin and metalloprotease with
thrombospondin motifs (ADAMTS)-5 expression and rescued the
IL-1b-dependent repression of aggrecan gene expression82. Trans-
fection of synthetic miR-146a showed that IL-1 induced expression
of MMP-13 and ADAMTS-5 were suppressed in human knee
chondrocytes, and inﬂammatory cytokines (IL-6, IL-8) were
inhibited in synovial cells103. Besides, exogenous supplementation
of synthesis miR-146a prominently decreased inﬂammatory cyto-
kines and pain-related molecules in human glial cells, such as TNF-
a, COX-2, iNOS, IL-6 and IL-8103.
Conclusion
As discussed above, OA, inﬂammation and MetS are well
correlated, and meta-inﬂammation plays an important role in the
pathogenesis of OA. Obesity induced chronic, low-grade inﬂam-
matory responses initiated by excess nutrients in metabolic cells
results in a series of pro-inﬂammatory changes in OA. Targeting
components of meta-inﬂammation, such as body fat, adipokines,
cytokines, acute-phase inﬂammatory components, excessive
metabolites or nutrients, vitamin D deﬁciency and miRNAs,
would constitute novel ways for the prevention and treatment of
OA, especially those with metabolic phenotype. So far, OA pa-
tients who lose weight have shown improvements in pain and
physical function, with decreased low-grade inﬂammation;
however, strategies aiming at reducing body fat and increasing
muscle mass or strength would be more effective. NO inhibitors
and antioxidants may modulate meta-inﬂammation, but so far
their clinical efﬁcacies for the treatment of OA are not promising.
Other strategies that can regulate meta-inﬂammation, such as
anti-cytokine therapies, lipid-modiﬁcation by statins, vitamin D
supplementation, progressive resistance training and anti-
miRNAs/miRNA-mimics, are under extensive investigation.These therapies may prove to be effective, and can provide
innovative approaches for OA management.
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